Benzothiadiazoles
eMolecules 4-IODO-2,1,3-BENZOTHIADIAZOLE | 352018-95-2 | 1G | Purity: 95%
AstaTech | 4-IODO-2,1,3-BENZOTHIADIAZOLE | 1G | 352018-95-2 | MFCD02681904
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
Medchemexpress LLC FAUC 213 | 337972-47-1 | 99.9% | C18H19ClN4 | 50 MG
FAUC 213 is an orally active and highly selective dopamine D4 receptor complete antagonist with a Ki of 2.2 nM for hD4.4. It shows less activity on D2 and D3 receptors, with Kis of 3.4 μM and 5.3 μM respectively. This compound can cross the blood-brain barrier (BBB) and exhibits atypical antipsychotic characteristics.
- Highly selective dopamine D4 receptor complete antagonist
- Orally active
- Crosses the blood-brain barrier (BBB)
- Exhibits atypical antipsychotic characteristics
- Inhibits p5-HT1 (Ki=1.2 μM), p5-HT2 (Ki=0.52 μM), and pα1 (Ki=0.27 μM)
- Significantly reduces amphetamine-induced locomotor hyperactivity at 30 mg/kg
- Restores prepulse inhibition reduction caused by apomorphine treatment at 30 mg/kg
Apexbio Technology LLC KD 5170 940943-37-3 10mM (in 1mL DMSO)
KD 5170 (CAS 940943-37-3) is a small-molecule inhibitor targeting histone deacetylases (HDACs) enzymes that catalyze the removal of acetyl groups from histones repressing transcription KD 5170 inhibits HDAC enzyme activity exhibiting distinct inhibitory potency against HDAC isoforms HDAC1 HDAC2 HDAC3 HDAC4 and HDAC6 (IC50 values 0 020 2 0 0 075 0 026 and 0 014 M respectively) In vitro KD 5170 promotes dose-dependent histone hyperacetylation (EC50 25 nM in HeLa cells) and enhances p21WAF1 expression and -tubulin acetylation in HCT-116 cells It has demonstrated antitumor effects reducing tumor growth and increasing histone acetylation in HCT-116 and H929 tumor xenograft mouse models validating its utility in cancer research
Medchemexpress LLC FAUC 213 | 337972-47-1 | 99.9% | C18H19ClN4 | 25 MG
FAUC 213 is an orally active and highly selective dopamine D4 receptor complete antagonist with a Ki of 2.2 nM for hD4.4. It shows less activity on D2 and D3 receptors (Kis of 3.4 μM and 5.3 μM for hD2 and hD3, respectively). FAUC 213 can cross the blood-brain barrier (BBB) and exhibits atypical antipsychotic characteristics. It is for research use only and not sold to patients.
- Targets hD4.4 receptor (Ki = 2.2 nM), hD2 receptor (Ki = 3.4 μM), hD3 receptor (Ki = 5.3 μM)
- Inhibits p5-HT1 (Ki=1.2 μM), p5-HT2 (Ki=0.52 μM), pα1 (Ki=0.27 μM) in vitro
- Significantly reduces amphetamine-induced locomotor hyperactivity with pre-treatment of 30 mg/kg in vivo
- Significantly restores prepulse inhibition reduction caused by apomorphine treatment with 30 mg/kg in vivo
![Medchemexpress LLC S-[2-[6-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonylamino]-3-pyridinyl]-2-oxoethyl] ethanethioate | 940943-37-3 | MFCD19690928 | 98.1% | 451.56 | C20H25N3O5S2 | 10 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000241454.png-250.jpg)
Medchemexpress LLC S-[2-[6-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonylamino]-3-pyridinyl]-2-oxoethyl] ethanethioate | 940943-37-3 | MFCD19690928 | 98.1% | 451.56 | C20H25N3O5S2 | 10 MG
KD 5170 is a small-molecule pan inhibitor of histone deacetylases (HDACs) that demonstrates broad-spectrum antitumor activity in vitro and in vivo. It is offered for laboratory research use and includes recommended solubility and storage guidance for experimental applications.
- Pan inhibitor of histone deacetylases (HDACs).
- Demonstrates broad-spectrum antitumor activity in vitro and in vivo.
- High purity (≈98.1%).
- Molecular formula C20H25N3O5S2; molecular weight 451.56.
- Soluble in DMSO (100 mg/mL); in vivo formulations documented at 2.5 mg/mL in common vehicles.
- Store sealed at 4°C; in solvent store at -80°C for long-term stability.
Sigma Aldrich Fine Chemicals Biosciences Tizanidine Related Compound A30536-19-7 | MFCD00465908 | 50mg
Tizanidine Related Compound A | MW:185.63 | 30536-19-7 | MFCD00465908 | 50mg
Accela Chembio Inc 2 | 1 | 3-benzothiadiazole | 100g | 273-13-2 | MFCD00005809 | 97+% | Shelf Life: 1260 Days | Light Sensitive/+4
2 | 1 | 3-benzothiadiazole | 100g | 273-13-2 | MFCD00005809 | 97+% | Shelf Life: 1260 Days | Light Sensitive/+4
eMolecules 4-IODO-2,1,3-BENZOTHIADIAZOLE | 352018-95-2 | 5G | Purity: 95%
AstaTech | 4-IODO-2,1,3-BENZOTHIADIAZOLE | 5G | 352018-95-2 | MFCD02681904
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
![Medchemexpress LLC S-[2-[6-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonylamino]-3-pyridinyl]-2-oxoethyl] ethanethioate | 940943-37-3 | MFCD19690928 | 98.1% | 451.56 g·mol⁻¹ | C20H25N3O5S2 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000240833.png-250.jpg)
Medchemexpress LLC S-[2-[6-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonylamino]-3-pyridinyl]-2-oxoethyl] ethanethioate | 940943-37-3 | MFCD19690928 | 98.1% | 451.56 g·mol⁻¹ | C20H25N3O5S2 | 25 MG
KD 5170 is a mercaptoketone-based pan inhibitor of histone deacetylases (HDACs) that demonstrates broad-spectrum antitumor activity in vitro and in vivo. It is supplied as a white to yellow solid for research use only.
- Potent pan-histone deacetylase (HDAC) inhibition.
- Demonstrated broad-spectrum antitumor activity in vitro and in vivo.
- High reported purity (≈98.1%).
- Available in small-mass pack sizes suitable for preclinical studies.
- White to yellow solid form, convenient for storage and handling.
- Intended for research use only and not for human therapeutic use.
